ENvue Medical, Inc.
Close on Oct 19, 2026
- Market cap
- $3.08M
- P/E (TTM)
- –
- Dividend yield
- –
About ENvue Medical
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
ENvue Medical, Inc. develops, manufactures, and markets medical devices specializing in enteral feeding navigation and non-invasive therapeutic solutions. Its core offering is the ENvue System, an electromagnetic navigation platform that guides clinicians in the real-time placement and verification of enteral feeding tubes into the stomach or small intestine of adult hospital patients. Alongside the navigation console, the company provides proprietary single-use feeding tubes and related accessories such as syringes. Through its subsidiary NanoVibronix Ltd., the company also develops wearable, non-invasive acoustic devices for biofilm prevention and pain therapy, designed for direct patient use at home without medical professional oversight.
The company primarily targets the acute care hospital sector in the United States, maintaining active commercial relationships with multiple American hospitals for clinical evaluation and use. In addition, its products have selective distribution in Europe, Australia, and New Zealand. Corporate headquarters are situated in Tyler, Texas, with additional corporate operations based in Israel.
Summary of the business section of ENvue Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ENvue Medical, Inc.
- Founded
- 2003
- Headquarters
- Tyler, TX
- Address
- 969 Pruitt Ave, 77569
- Phone
- (914) 233-3004
- Employees
- 7, Dec 31, 2025
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KOST FORER GABBAY & KASIERER, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- FEED
- Exchange
- OTC
- IPO date
- May 28, 2015
- Shares outstanding
- 11M, Aug 17, 2026
- Public float
- $7.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Sep 1, 2026; 1-for-10 reverse, Aug 19, 2025; 1-for-10 reverse, Aug 12, 2025; 1-for-11 reverse, Mar 14, 2025; 1-for-20 reverse, Apr 17, 2023; 1-for-20 reverse, Feb 9, 2023
- SEC CIK
- 1326706
- CUSIP
- 29415F100
- ISIN
- US29415F1007
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brian M. Murphy | Chief Executive Officer, Director | – |
| Harold Jacob | Chief Medical Officer, Director | 89,840 |
| Nicole M. Fernandez-McGovern | Interim CFO | – |
| Stephen Russell Brown | Chief Financial Officer | 4,000 |
| Zeev Jhoshua Rotstein | Director | – |
| Alison Burgett | Director | – |
| David Ian Johnson | Director | – |
| Pellegrino Pionati | Director | – |
| Maria Schroeder | Director | – |
| Michael Ferguson | Director | – |
| Thomas Mika | Director | 50,000 |
| Martin M. Goldstein | Director | – |
| Christopher M. Fashek | Director | 25,000 |
| Aurora Cassirer | Director | 2,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Brian Murphy | $424.04K | $424.04K | $306.22K | $51 | – |
| FY2023 Brian Murphy | $541.86K | $309.77K | $361.67K | $27 | – |
| FY2022 Brian Murphy | $408.80K | $110.35K | $298.60K | $36 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of the date of this Annual Report on Form 10-K, we had 7 employees, 9 contractors, and 5 non-employee”
Corporate history
Events identified from SEC filings